• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Surg Case Rep . The impact of COVID-19 on delayed presentations of necrotising fasciitis

tetano

Editor, Senior Moderator
J Surg Case Rep


. 2022 Feb 6;2022(2):rjac015.
doi: 10.1093/jscr/rjac015. eCollection 2022 Feb.
The impact of COVID-19 on delayed presentations of necrotising fasciitis


Quoc Dung Nguyen[SUP] 1 2 [/SUP], Jason Diab[SUP] 1 3 [/SUP], David Khaicy[SUP] 3 [/SUP], Vanessa Diab[SUP] 3 [/SUP], Zachias Hopkins[SUP] 3 [/SUP], Lai Heng Foong[SUP] 1 2 [/SUP], Christophe R Berney[SUP] 1 2 [/SUP]



Affiliations

Abstract

The purpose of this study was to determine the impact of coronavirus disease 2019 (COVID-19) on the delayed presentation of necrotising fasciitis (NF). A retrospective study was conducted of adult patients (≥16 years old) diagnosed with NF at a hospital from 2017 to 2020. A quantitative comparative analysis for the COVID-19 group and control group between 2017 and 2019. Structured interviews were conducted to examine the impact of COVID-19 on patients. There were 6 patients in the COVID-19 group and 10 patients in the control group. The COVID-19 group had a longer mean onset of symptoms till hospital presentation of 4.1 days and a longer mean operative time. The COVID-19 group was more likely to be admitted to intensive care unit. Three patients in the COVID-19 group did not survive compared to survival in the counterparts. Participant responses indicated the COVID-19 pandemic did not prevent them from presenting to ED.
 
Back
Top Bottom